Prognostic implications of HPV in oropharyngeal cancer

New England Journal of Medicine

Volumn 363, Issue 1, 2010, Pages 82-84

  Lowy, Douglas R ^a   Munger, Karl ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN P16; PROTEIN P53;

CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TOBACCO DEPENDENCE; TREATMENT RESPONSE; UTERINE CERVIX CANCER; WART VIRUS;

EID: 77954208224     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1003607     Document Type: Editorial

References (15)

1. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008;113:7 Suppl: 1980-93.
2. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46:S20-S26.
3. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
4. Dahlstrand H, Näsman A, Romanitan M, Lindquist D, Ramqvist T, Dalianis T. Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 2008;28:1133-8. (Pubitemid 351578850)
5. Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008;22:1125-42.
6. Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol 2009;21:201-5.
7. McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses. Virus Res 2009;143:195-208.
8. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomaviruspositive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007;67:4605-19.
9. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent on the treatment modality? Int J Cancer 2010;126:1256-62.
10. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007;86:506-11.
11. Smith EM, Rubenstein LM, Ritchie JM, et al. Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomarkers Prev 2008;17:2087-96.
12. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1137-46.
13. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101:412-23.
14. Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F. Cellular responses of HPV-positive cancer cells to genotoxic anticancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 1996;68:506-13.
15. Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res 2010;16:2138-46.